Advanced Biomed INC

Advanced Biomed Inc. has terminated its $25 million share purchase agreement with Helena Global Investment Opportunities I Ltd., effective July 21, 2026.

Advanced Biomed Inc. announced the results of its annual meeting of stockholders held on June 30, 2026, where all director nominees were elected and key proposals were approved.

Advanced Biomed Inc. has entered into a Share Purchase Agreement to sell its wholly-owned Taiwan subsidiary, which handles its biomedical R&D, for $490,000.

Advanced Biomed Inc. is transitioning from life sciences to artificial intelligence, appointing Xiaomin Chen as CEO following the acquisition of Acellent Technologies.

Advanced Biomed Inc. has entered into a material definitive agreement for a $600,000 unsecured loan with Jie Wang, to be used for operational purposes.

Advanced Biomed Inc. has entered into a Share Purchase Agreement to acquire Acellent Technologies (Hong Kong) Co. Limited, an AI-powered financial verification and audit solutions provider.

Advanced Biomed Inc. reports a net income of $5.98 million for the nine months ended March 31, 2026, driven by a significant gain from subsidiary disposal, alongside increased R&D spending and a strategic shift towards AI.

Advanced Biomed Inc. reported a significantly wider net loss and increased cash burn from operations for the quarter ended September 30, 2025, raising substantial doubt about its ability to continue as a going concern.

Advanced Biomed Inc. reports its Q3 2025 results, highlighting its recent IPO and ongoing research and development efforts in microfluidic biochip technology for oncology.

Advanced Biomed Inc. reports a net loss for the quarter ended December 31, 2024, as it continues to invest in research and development and navigate regulatory approvals for its cancer detection and diagnosis technologies.

Advanced Biomed Inc. reported significant net losses and negative operating cash flows for fiscal year 2025, alongside a Nasdaq minimum bid price non-compliance notice, while advancing product development and global expansion plans.

Advanced Biomed Inc. has filed its proxy statement for the Annual Meeting of Stockholders on June 30, 2026, detailing proposals including director elections, executive compensation votes, and auditor ratification.

Advanced Biomed Inc. announces a planned reverse stock split, ranging from 1:2 to 1:100, to maintain its listing on The Nasdaq Capital Market.

Advanced Biomed Inc., a pre-revenue biotechnology company, filed an S-1 registration statement for the resale of up to 40 million shares by a selling stockholder under a $25 million equity line of credit, while grappling with persistent net losses and a Nasdaq minimum bid price deficiency.

Advanced Biomed Inc. is seeking to raise capital through an initial public offering of 1,875,000 shares of common stock, aiming for a Nasdaq listing to further its cancer detection technology.

Advanced Biomed Inc., a Nevada-based holding company focused on integrating semiconductor technology and biotechnology for cancer diagnostics, has filed Amendment No. 15 to its Form S-1 registration statement for a proposed initial public offering.

Advanced Biomed Inc., a Nevada-based holding company, plans to raise capital through a $7.5 million common stock offering to fund cancer detection technology development and market expansion.

Advanced Biomed Inc., a Nevada-based holding company focused on integrating semiconductor technology and biotechnology for cancer detection, has filed Amendment No. 13 to its Form S-1 registration statement for a proposed public offering of 1,875,000 shares of common stock.